Panama and El Salvador Children's Oseltamivir Study

Exclusion Criteria

• •Symptom onset 7 days or more at the time of study screening where day 1 is the day of symptom onset
• •Concomitant severe vomiting illness prior to enrollment that would preclude ability to take medication orally defined as more than 3 vomiting episodes in the preceding 24 hours
• •Prematurity (birth at less than 37 weeks gestation) for children aged less than 3 months
• •Birth weight less than 2500 grams for children aged less than 3 months
• •Chronic supplemental oxygen requirement at home
• •Known history of renal dysfunction
• •History of gastrointestinal resection resulting in gastrointestinal abnormality that might hinder absorption of oral medication (such as short-gut syndrome)
• •History of previous serious adverse reaction to oseltamivir phosphate
• •Receipt of oseltamivir phosphate during the 5 days prior to presentation at the admitting hospital
• •Previous enrollment in this study during a hospitalization that ended less than 14 days prior to the current admission